Impact of AD Co‐Pathology on Response to Neflamapimod (p38α Kinase Inhibitor) in Patients with Dementia with Lewy Bodies

Abstract

Background: Neflamapimod (oral drug that targets cholinergic dysfunction and degeneration) was recently reported in the RewinD‐LB Phase 2b study in patients with DLB without AD co‐pathology to meaningfully impact clinical progression, assessed by CDR‐SB. Exclusion criteria for AD co‐pathology (≥ 2.

The paper